97
Participants
Start Date
December 4, 2020
Primary Completion Date
September 20, 2029
Study Completion Date
December 19, 2029
Genetic: AAV5-hRKp.RPGR Intermediate Dose
Bilateral, subretinal administration of AAV5-hRKp.RPGR - deferred treatment group
Genetic: AAV5-hRKp.RPGR Low Dose
Bilateral, subretinal administration of AAV5-hRKp.RPGR - deferred treatment group
Universite de Lausanne, Hopital ophtalmique Jules-Gonin, Lausanne
Rigshospitalet Glostrup, Glostrup Municipality
University Hospital Basel, Eye Clinic/Institute of Molecular and Clinical, Basel
Ghent University Hospital, Ghent
University of Pittsburgh Medical Center (UPMC), Pittsburgh
Ospedale San Paolo, Milan
Duke Eye Center, Durham
Hosp Univ Fund Jimenez Diaz, Madrid
Emory University, Atlanta
VitreoRetinal Associates, PA, Gainesville
Univ of Michigan Medical Center, Ann Arbor
Azienda Ospedaliero Universitaria Careggi, Florence
Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts, Paris
Retina Consultants of Houston, Bellaire
Azienda Ospedaliera Univ.- Università Degli studi della Campania - Luigi Vanvitelli, Napoli
Childrens Hospital Los Angeles, Los Angeles
Hadassah Medical Center, Jerusalem
Stanford Health Care, Palo Alto
Shiley Eye Institute Jacobs Retina Center, La Jolla
Massachusetts Eye and Ear Infirmary, Boston
Hospital For Sick Children, Toronto
IRCCS Fondazione G.B. Bietti per lo Studio e la Ricerca in Oftalmologia ONLUS, Rome
VUMC Amsterdam, Amsterdam
Radboudumc, Nijmegen
NHS Lothian, Edinburgh
Gartnavel General Hospital, Glasgow
St James University Hospital, Leeds
Moorfields Eye Hospital, London
Janssen Research & Development, LLC
INDUSTRY